A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays

Toxicology in Vitro

Volumn 27, Issue 2, 2013, Pages 560-569

  Hynes, James ^a   Nadanaciva, Sashi ^b   Swiss, Rachel ^b   Carey, Conn ^a   Kirwan, Sinead ^a   Will, Yvonne ^b  

^a Luxcel Biosciences Ltd   (Ireland)

^b PFIZER INC   (United States)

Author keywords

Extracellular acidification; Mitochondrial dysfunction; Oxygen consumption; Respiration; Toxicity

Indexed keywords

AMIODARONE; BENZBROMARONE; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; CHLORMEZANONE; CICLOPIROX; CITRININ; CLOMIFENE; DIFLUNISAL; FIPEXIDE; FLUTAMIDE; GALACTOSE; GLUCOSE; HEXACHLOROPHENE; IMIPRAMINE; KETOCONAZOLE; MENADIONE; NEFAZODONE; NIMESULIDE; OLIGOMYCIN; OXAMIC ACID; PAMIDRONIC ACID; PAROXETINE; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PIMOZIDE; RILUZOLE; ROTENONE; SERTRALINE; TAMOXIFEN; UNINDEXED DRUG;

ACIDIFICATION; ARTICLE; ASSAY; CELL STRAIN HEPG2; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG CYTOTOXICITY; HIGHT THROUGHPUT DUAL PARAMETER ASSAY; HUMAN; HUMAN CELL; LIVER MITOCHONDRION; MALE; MITOCHONDRIAL TOXICITY; NONHUMAN; OXYGEN CONSUMPTION; RAT; REPRODUCIBILITY; TOXICITY TESTING; VALIDATION PROCESS;

ADENOSINE TRIPHOSPHATE; ANIMALS; BIOLOGICAL ASSAY; CELL LINE; DRUG TOXICITY; HEP G2 CELLS; HL-60 CELLS; HUMANS; MALE; MITOCHONDRIA, LIVER; OXYGEN CONSUMPTION; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS;

EID: 84875277824     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.11.002     Document Type: Article

References (55)

1. Amacher D.E. Drug-associated mitochondrial toxicity and its detection. Curr. Med. Chem. 2005, 12:1829-1839.
2. Arena J.P., Kass R.S. Block of heart potassium channels by clofilium and its tertiary analogs: relationship between drug structure and type of channel blocked. Mol. Pharmacol. 1988, 34:60-66.
3. Balijepalli S., Boyd M.R., Ravindranath V. Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology 1999, 38:567-577.
4. Beeson C.C., Beeson G.C., Schnellmann R.G. A high-throughput respirometric assay for mitochondrial biogenesis and toxicity. Anal. Biochem. 2010, 404:75-81.
5. Berson A., Cazanave S., Descatoire V., Tinel M., Grodet A., Wolf C., Feldmann G., Pessayre D. The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: protection by albumin. J. Pharmacol. Exp. Ther. 2006, 318:444-454.
6. Boelsterli U.A., Ho H.K., Zhou S., Leow K.Y. Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr. Drug Metab. 2006, 7:715-727.
7. Brown D.A., O'Rourke B. Cardiac mitochondria and arrhythmias. Cardiovasc. Res. 2010, 88:241-249.
8. Cammer W., Moore C.L. The effect of hexachlorophene on the respiration of brain and liver mitochondria. Biochem. Biophys. Res. Commun. 1972, 46:1887-1894.
9. Clark, L.C., 1959. Electrochemical device for chemical analysis. US patent no. 2913386.
10. Durand F., Samuel D., Bernuau J., Saliba F., Pariente E.A., Marion S., Benhamou J.P., Bismuth H. Fipexide-induced fulminant hepatitis. Report of three cases with emergency liver transplantation. J. Hepatol. 1992, 15:144-146.
11. Dykens J.A. RedOx targets: enzyme systems and drug development strategies for mitochondrial dysfunction. Comprehensive Medicinal Chemistry 2007, vol. II. II. Elsevier, Oxford, UK, pp. 1053-1087.
12. Dykens J.A., Jamieson J., Marroquin L., Nadanaciva S., Billis P.A., Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol. Appl. Pharmacol. 2008, 233:203-210.
13. Dykens J.A., Jamieson J.D., Marroquin L.D., Nadanaciva S., Xu J.J., Dunn M.C., Smith A.R., Will Y. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci. 2008, 103:335-345.
14. Dykens J.A., Marroquin L.D., Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Exp. Rev. Mol. Diagn. 2007, 2:161-175.
15. Dykens J.A., Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 2007, 12:777-785.
16. Eto K., Fukuda T., Araki Y., Inoue B., Ogata M. Effect of tricyclic drugs on mitochondrial membrane. Acta Med. Okayama 1985, 39:289-295.
17. Evans M., Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?. Drug Saf. 2002, 25:649-663.
18. Fromenty B., Fisch C., Labbe G., Degott C., Deschamps D., Berson A., Letteron P., Pessayre D. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J. Pharmacol. Exp. Ther. 1990, 255:1371-1376.
19. Gardos G., Cole J.O. Weight reduction in schizophrenics by molindone. Am. J. Psychiatry 1977, 134:302-304.
20. Hasumi H., Matsuda R., Shimamoto K., Hata Y., Kaneko N. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization. Eur. J. Pharmacol. 2007, 555:54-60.
21. Hirschberg R. Renal complications from bisphosphonate treatment. Curr. Opin. Support. Palliat. Care 2012, 6:342-347.
22. Hynes J., Marroquin L.D., Ogurtsov V.I., Christiansen K.N., Stevens G.J., Papkovsky D.B., Will Y. Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol. Sci. 2006, 92:186-200.
23. Hynes J., Marroquin L.D., Ogurtsov V.I., Christiansen K.N., Stevens G.J., Papkovsky D.B., Will Y. Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol. Sci. 2007, 92:186-200.
24. Hynes J., Natoli E., Will Y. Fluorescent pH and oxygen probes of the assessment of mitochondrial toxicity in isolated mitochondria and whole cells. Curr. Protoc. Toxicol. 2009, (unit 2.16).
25. Hynes J., O'Riordan T.C., Papkovsky D.B. The use of oxygen sensitive fluorescent probes for the assessment of mitochondria function. Drug-Induced Mitochondrial Dysfunction 2008, 353-371. John Wiley & Sons, NJ. Y. Will, J.A. Dykens (Eds.).
26. Hynes J., O'Riordan T.C., Zhdanov A.V., Uray G., Will Y., Papkovsky D.B. In vitro analysis of cell metabolism using a long-decay ph-sensitive probe and extracellular acidification assay. Anal. Biochem. 2009, 390:21-28.
27. Hynes J., Swiss R.L., Will Y. High-throughput analysis of mitochondrial oxygen consumption. Methods Mol. Biol. 2012, 810:59-72.
28. Jackson M., Llado J., Rothstein J.D. Therapeutic developments in the treatment of amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs 2002, 11:1343-1364.
29. Kashimshetty R., Desai V.G., Kale V.M., Lee T., Moland C.L., Branham W.S., New L.S., Chan E.C., Younis H., Boelsterli U.A. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 2009, 238:150-159.
30. Kaufmann P., Torok M., Hanni A., Roberts P., Gasser R., Krahenbuhl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005, 41:925-935.
31. Kaufmann P., Torok M., Zahno A., Waldhauser K.M., Brecht K., Krahenbuhl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell. Mol. Life Sci. 2006, 63:2415-2425.
32. Li Y., Couch L., Higuchi M., Fang J.L., Guo L. Mitochondrial dysfunction induced by sertraline, an antidepressant agent. Toxicol. Sci. 2012, 127:582-591.
33. Marroquin L.D., Hynes J., Dykens J.A., Jamieson J.D., Will Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 2007, 97:539-547.
34. Maurer I., Moller H.J. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell. Biochem. 1997, 174:255-259.
35. McDougall P., Markham A., Cameron I., Sweetman A.J. The mechanism of inhibition of mitochondrial oxidative phosphorylation by the nonsteroidal anti-inflammatory agent diflunisal. Biochem. Pharmacol. 1983, 32:2595-2598.
36. Menor C., Fernandez-Moreno M.D., Fueyo J.A., Escribano O., Olleros T., Arriaza E., Cara C., Lorusso M., Di Paola M., Roman I.D., Guijarro L.G. Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-l-cysteine. J. Pharmacol. Exp. Ther. 2004, 311:668-676.
37. Moreno-Sanchez R., Bravo C., Vasquez C., Ayala G., Silveira L.H., Martinez-Lavin M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem. Pharmacol. 1999, 57:743-752.
38. Moreno S.N. Pentamidine is an uncoupler of oxidative phosphorylation in rat liver mitochondria. Arch. Biochem. Biophys. 1996, 326:15-20.
39. Nadanaciva S., Dykens J.A., Bernal A., Capaldi R.A., Will Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol. Appl. Pharmacol. 2007, 223:277-287.
40. Nadanaciva S., Lu S., Gebhard D.F., Jessen B.A., Pennie W.D., Will Y. A high content screening assay for identifying lysosomotropic compounds. Toxicol. In Vitro 2011, 25:715-723.
41. Nakaue H.S., Caldwell R.S., Buhler D.R. Bisphenols-uncouplers of phosphorylating respiration. Biochem. Pharmacol. 1972, 21:2273-2277.
42. O'Bryant C.L., Flaig T.W., Utz K.J. Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy 2008, 28:1071-1075.
43. Ong M.M., Wang A.S., Leow K.Y., Khoo Y.M., Boelsterli U.A. Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/-) mice. Free Radic. Biol. Med. 2006, 40:420-429.
44. Pessayre D., Berson A., Fromenty B. Drug-induced mitochondrial dysfunction. Drug-Induced Mitochondrial Dysfunction 2008, 143-202. John Wiley & Sons, Hoboken, NJ. J.A. Dykens, Y. Will (Eds.).
45. Remy A.J., Camu W., Ramos J., Blanc P., Larrey D. Acute hepatitis after riluzole administration. J. Hepatol. 1999, 30:527-530.
46. Rodriguez R.J., Acosta D. Inhibition of mitochondrial function in isolated rate liver mitochondria by azole antifungals. J. Biochem. Toxicol. 1996, 11:127-131.
47. Ruben L., Rasmussen H. Phenothiazines and related compounds disrupt mitochondrial energy production by a calmodulin-independent reaction. Biochim.Biophys. Acta 1981, 637:415-422.
48. Sehgal V.N. Ciclopirox: a new topical pyrodonium antimycotic agent. A double-blind study in superficial dermatomycoses. Br. J. Dermatol. 1976, 95:83-88.
49. Sleno L., Staack R.F., Varesio E., Hopfgartner G. Investigating the in vitro metabolism of fipexide: characterization of reactive metabolites using liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:2301-2311.
50. Sneyd J.R. Droperidol: past, present and future. Anaesthesia 2009, 64:1161-1164.
51. Tuquet C., Dupont J., Mesneau A., Roussaux J. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria. Cell Biol. Toxicol. 2000, 16:207-219.
52. Wallace K.B. Mitochondrial off targets of drug therapy. Trends Pharmacol. Sci. 2008, 29:361-366.
53. Wallace K.B., Starkov A. Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 2000, 40:353-388.
54. Will Y. Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat. Protoc. 2007, 1:2563-2572.
55. Zhou S., Wallace K.B. The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol. Sci. 1999, 48:82-89.